Vertex Pharmaceuticals Incorporated is a Massachusetts-based biotechnology company that develops and commercializes medicines for serious diseases, with its current commercial portfolio concentrated in cystic fibrosis treatments including TRIKAFTA/KAFTRIO, ALYFTREK, KALYDECO, ORKAMBI, SYMDEKO/SYMKEVI, and CASGEVY for sickle cell disease and beta thalassemia. The company also has a pain medicine JOURNAVX approved and a pipeline candidate povetacicept in late-stage development for immunoglobulin A nephropathy and other indications. Vertex trades on the Nasdaq Global Select Market under the ticker VRTX and is incorporated in Massachusetts.

What is VRTX's DredgeCap risk score?

DredgeCap's AI analysis rates VRTX at 3.2/10 on the risk scale — Low risk. This score reflects dilution exposure, debt toxicity, liquidity position, and going-concern posture as disclosed in SEC filings.

Does VRTX have a going concern warning?

No current auditor going-concern warning is flagged in VRTX's SEC filings. Risk assessment is based on other filing-disclosed factors.

When did VRTX last file with the SEC?

VRTX's most recent SEC filing was a 8-K filed 2026-03-31. All filings are available on SEC EDGAR.

← VRTX Overview

10-QMay 5, 2026· Quarter Ended March 31, 2026

VRTX — 10-Q Filing

Track VRTX for Alerts

VRTX 10-Q Summary

For the quarter ended March 31, 2026, Vertex Pharmaceuticals Inc / Ma reported revenue of $2.99B, up 7.8% year-over-year. Operating income was $1.14B, up 1138063.0% year-over-year; net income was $1.03B, up 59.6% year-over-year.

VRTX Financial Highlights

Metric

Q-End 03/26

Q-End 03/25

Revenue

$2.99B

$2.77B

▲+7.8% YoY

Operating Income

$1.14B

$0.1M

▲+1138063.0% YoY

Net Income

$1.03B

$646.3M

▲+59.6% YoY

VRTXWhat's Driving the Change

Depreciation & amortization

up 566.0% from $8.4M a year earlier

$55.9M

▲

Asset impairment

down 100.0% from $379.0M a year earlier

$0.0M

▼

Current DredgeCap Risk Profile

Risk Score

3.2/10

MODERATE

Dilution

1.8

Debt Toxicity

1.5

Going Concern

✓ Not flagged

The risk profile above reflects the latest cached DredgeCap analysis for VRTX. For the full filing-by-filing analyst report (red flags, primary risk driver, what moves the stock), open VRTX's company page.

What is a 10-Q?

A quarterly report covering the three months just ended. Includes unaudited condensed financial statements (balance sheet, income statement, cash flow), Management Discussion and Analysis (MD&A), and disclosure of material changes since the last annual report. Required for the first three fiscal quarters; the fourth quarter is rolled into the 10-K.

More on VRTX

Financial highlights are sourced directly from the 10-Q income statement (three months ended). YoY % compares to the same quarter one year earlier as reported by the issuer. The plain-language summary above is composed mechanically from the filing's reported numbers — no analysis or opinion. Form-type explainers and 8-K item descriptions are derived from SEC documentation. This page does not constitute investment advice. Always consult the original filing on SEC EDGAR for authoritative content, and consult a licensed financial advisor for investment decisions.